Using infrared technology, we provide a non-invasive, painless, private, and accurate adjunct breast cancer screening in under 10 minutes. Our Eva Centers are located in shopping centers.

Egress Health builds AI agents to automate revenue cycle management, starting with dental offices. Our workflows span eligibility checks, claims scrubbing, payment posting, and denial management. On average, our customers eliminate 1-2 full time employees and collect 5-15% more revenue each month. Interested in learning more? Shoot us a note at founders@tryegress.com

Healthcare is delivered by teams – nurses, doctors, and staff, specific to each hospital, clinic, and department. They want to do their best, but cannot keep up with constantly changing information. Burnout >50%. Unprecedented turnover. Growing medical errors (the #3 cause of death in the US). $100B+ in waste. Elemeno Health is a UCSF and Y Combinator-backed B2B SaaS for healthcare facilities– “a playbook in your pocket,” customized to support frontline teams with bite-sized training and communication at their fingertips, accessible 24/7 on any device. Our efficacy is demonstrated in our published results, passionate clients, and consistent renewals. 20x ROI. 75% decrease in medical errors.

Eligible is the nation's first insurance billing platform built for builders. Founded in Mountain View California in 2011, Eligible's platform gives bootstrapping healthcare startups the scale of enterprise, and the Fortune 500s the agility of the hungry entrepreneur. Eligible has been listed as one of Business Insider’s 19 Hottest Startups to Watch and Katelyn has been featured in Forbes 30 Under 30 in Healthcare, Fast Company's Most Creative People in Business, and was named a Rising Star of Healthcare by Becker’s IT & CIO Review.

Over 80% of maternal mortalities were preventable with earlier intervention. Currently, doctors miss >50% of moms who have life-threatening complications and wait until labor to start doing manual risk assessments, at which point it's too late. Elythea's proprietary ML models catch life-threatening obstetric complications (like postpartum hemorrhage, preeclampsia/eclampsia, emergency c-section, preterm labor, and more) as soon as the first visit. We automatically analyze relevant demographic and clinical risk factors, flag high-risk patients, and provide evidence-based interventions, giving doctors months in advance to intervene and prevent complications from ever happening. Our global clinical studies have shown that we can catch 3x more complications than clinical judgment 10x sooner.

At Ember, we're tackling one of healthcare's most costly and overlooked challenges: the massive inefficiency in clinical documentation and revenue cycle management. Medical practices lose billions annually due to incomplete documentation, missed billing opportunities, and denied claims - issues that stem from antiquated systems that force clinicians to choose between patient care and paperwork. We combine ambient listening technology with deep understanding of medical billing requirements to eliminate the administrative burden that plagues healthcare providers.

Preventive heart health. Don't die of a heart attack -- use Empirical Health to measure 100+ biomarkers, predict your future risk of heart disease, and create a customized prevention plan with a doctor. We AI to deliver preventive health at scale. We're licensed, registered, and insured to deliver real medical care in 30+ US states covering 200m+ people.

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Endo Health is building voice as the new emotional engine for healthcare. Glow, our AI voice companion, delivers weight loss coaching through intimate interactions, forming the emotional bonds that drive lasting change. With 50M+ TikTok views, 12000+ minutes of monthly conversation, 2x MoM growth, and 40%+ D7 retention, we're building the front door into healthcare starting with weight loss. Built by a medical doctor, backed by General Catalyst and a16z speedrun.

Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.

Enflux makes motion capture clothing for the masses. We are a technology platform serving Virtual Reality, Fitness, and Health through our open API. Our customers include Hasbro, The Jim Henson Company, and many more.

Engage Bio is developing mRNA immunotherapies to defeat cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. Our approach is to provide cancer cells with instructions to make and gradually release our drugs within solid tumors. This local therapy allows us to eliminate tumors while sparing healthy distant tissues.

Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.

Entvin is building AI agents specifically designed to support regulatory teams in the life sciences industry. Our platform leverages AI to streamline workflows, automate complex tasks, and enhance efficiency throughout the regulatory process. By focusing on the unique needs of regulatory teams, we help companies navigate compliance, accelerate approvals, and reduce operational bottlenecks, all while ensuring data security and confidentiality.

Enzyme provides online quality management system software and supportive QA/RA consulting, helping life science companies with FDA approval and ongoing compliance. Enzyme staff has over 50 years of medical device industry experience, across several Fortune 500 companies and startups.

We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.

Equipt Health makes it easy for any healthcare company to offer prescription medical devices to patients. We handle the whole process: the packaging, the logistics, the clinical (via our provider network) and technical support, and the return of data from connected devices. We're starting with the diagnosis and treatment of sleep apnea at heliosleep.com.

We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.

We build health insurance for mid-sized companies that costs 20% less and provides more effective medical care.

Examedi is a healthcare-at-home marketplace in Latin America that sends nurses and lab technicians directly to patients’ homes for appointments. It’s like Uber, but for medical lab work.

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.